Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment
LM Cao, NN Zhong, Y Chen, ZZ Li, GR Wang, Y **ao… - Cancer Letters, 2024 - Elsevier
Head and neck squamous cell carcinoma (HNSCC) constitutes a significant global cancer
burden, given its high prevalence and associated mortality. Despite substantial progress in …
burden, given its high prevalence and associated mortality. Despite substantial progress in …
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic …
Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has
improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC) …
improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC) …
Treatment-related adverse events, including fatal toxicities, in patients with extensive-stage small-cell lung cancer receiving adjuvant programmed cell death 1 …
Abstract Background/Aims The safety profile of programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) inhibitors when associated with chemotherapy …
1)/programmed cell death ligand 1 (PD-L1) inhibitors when associated with chemotherapy …
Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials
S Zhou, N Horita, T Shao… - … Advances in Medical …, 2024 - journals.sagepub.com
Background: Perioperative use of immune checkpoint blockade (ICB) improves survival in
patients with early-stage cancer. Treatment-related adverse events (AEs), frequently involve …
patients with early-stage cancer. Treatment-related adverse events (AEs), frequently involve …
Neoadjuvant chemoimmunotherapy complicates subsequent surgical resection and adjuvant immunotherapy is preferable from the surgical standpoint
PU Figueroa, V Lacroix, PE Van Schil - Journal of Thoracic Oncology, 2024 - Elsevier
In April 2022, Forde et al. 1 published the CheckMate 816 trial, the first ever phase 3 trial
reporting that neoadjuvant chemotherapy plus nivolumab followed by surgery offered …
reporting that neoadjuvant chemotherapy plus nivolumab followed by surgery offered …
Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
D O'Reilly, CL O'Leary, A Reilly, MY Teo… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
The combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs)
can be associated with significant toxicity. We performed a systematic review and meta …
can be associated with significant toxicity. We performed a systematic review and meta …
[HTML][HTML] A novel HVEM-Fc recombinant protein for lung cancer immunotherapy
Y Yao, B Li, J Wang, C Chen… - Journal of Experimental …, 2025 - pmc.ncbi.nlm.nih.gov
Background The ubiquitously expressed transmembrane protein, Herpesvirus Entry
Mediator (HVEM), functions as a molecular switch, capable of both activating and inhibiting …
Mediator (HVEM), functions as a molecular switch, capable of both activating and inhibiting …
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy …
Background Neoadjuvant chemoimmunotherapy has reshaped the treatment landscape for
resectable NSCLC, yet the prognostic significance of pathologic response remains unclear …
resectable NSCLC, yet the prognostic significance of pathologic response remains unclear …
Toxicity profiles of immunochemotherapy for gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
L Wan, F Tian, L Wang, Y Hou, W Liu, Q Liu, D Chen… - Cellular Oncology, 2024 - Springer
Purpose Neoadjuvant immunochemotherapy is emerging as a promising regimen for
patients with locally advanced gastric and gastroesophageal junction (G/GEJ) …
patients with locally advanced gastric and gastroesophageal junction (G/GEJ) …
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting
Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While
most patients are treated with immunotherapy, the use of targeted therapy is a valid …
most patients are treated with immunotherapy, the use of targeted therapy is a valid …